| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
5,385 |
4,387 |
$458K |
| J0178 |
Injection, aflibercept, 1 mg |
299 |
219 |
$252K |
| 92134 |
|
7,007 |
5,830 |
$128K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,093 |
2,636 |
$122K |
| J9035 |
Injection, bevacizumab, 10 mg |
1,718 |
1,434 |
$108K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
83 |
71 |
$81K |
| 92250 |
|
2,469 |
2,042 |
$80K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
294 |
260 |
$30K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
409 |
354 |
$22K |
| 67228 |
|
29 |
24 |
$16K |
| 92235 |
|
320 |
275 |
$12K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
730 |
594 |
$10K |
| J3590 |
Unclassified biologics |
1,173 |
872 |
$6K |
| 92201 |
|
91 |
71 |
$2K |
| 99426 |
|
105 |
96 |
$410.64 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
179 |
166 |
$108.63 |
| 2021F |
|
663 |
584 |
$5.84 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
119 |
96 |
$0.00 |